Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.155 1.57% 10.055 3,250,248 16:35:04
Bid Price Offer Price High Price Low Price Open Price
9.86 10.25 10.50 9.78 10.15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.08 -6.74 -3.99 25
Last Trade Time Trade Type Trade Size Trade Price Currency
16:33:43 O 400,000 9.80 GBX

Immupharma (IMM) Latest News

More Immupharma News
Immupharma Investors    Immupharma Takeover Rumours

Immupharma (IMM) Discussions and Chat

Immupharma (IMM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Immupharma trades in real-time

Immupharma (IMM) Top Chat Posts

DateSubject
10/4/2021
09:20
Immupharma Daily Update: Immupharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 9.90p.
Immupharma Plc has a 4 week average price of 8.10p and a 12 week average price of 8.10p.
The 1 year high share price is 21.30p while the 1 year low share price is currently 8.10p.
There are currently 250,221,297 shares in issue and the average daily traded volume is 2,004,704 shares. The market capitalisation of Immupharma Plc is £25,159,751.41.
18/2/2021
00:15
master rsi: I punt for the stock, because I know there is value at this price 9 to 10p There is so much negativity since the news that one sells, two sells and as the share price keeps going down, it becomes a roller coaster at the moment, has happened the same before, but came out rather well at the end.
15/2/2021
22:38
master rsi: I Buy T+20 as broker tells me is the same price, so it gives me all that time to play with. I buy to invest mostly, but I know the trend of most of those shares, and how much usually move, so If share price goes 25% plus and I was not expected to do so I will close and wait for the retrace that all shares do, otherwise I pay and wait for a proper rise. Plenty of them has risen 30 and 50% in a couple of weeks but I kept and still keeping, some mention earlier. Of the pharma, you reckon to know well, I had ODX and GDR for a few months, but both were sold last week on doubling on a couple of weeks, Director was selling today on ODX. I keep growing the Portfolio with the extra profits from the sharp risers. I already said too much, you may copy my strategy. One thing I can say, you will not beat me on timing. I have and shown my numbers you have NOT, just mouthy "gnome "
15/2/2021
12:25
master rsi: Strong buy - 100 target price - Navid Malik, analyst at The Life Sciences Please find below a note issued this morning from Navid Malik, analyst at The Life Sciences Division Summary: “ImmuPharma recently announced an update on the FDA meeting with Avion, ImmuPharma’s partner for Lupuzor™, on 4 December 2020 (Type ‘A’ meeting request). Based on the positive guidance and feedback from FDA, there is now a clear regulatory pathway to commence the Phase III trial in H2 2021, fully funded by Avion. As part of this feedback, Avion and ImmuPharma will develop and validate a bioanalytical assay in order to confirm the unique pharmacokinetic profile of Lupuzor™. This will be presented at the final guidance meeting between Avion and the FDA in Q2 as well as confirming the previously submitted data on study design, clinical end points and the pathway to approval. ImmuPharma is also having a new batch of Lupuzor™ manufactured ready for use in the Phase III clinical trial. Given the strengthened balance sheet position following the £6.5m placing in September 2020, a cash runway to end 2023, a fully funded Phase III trial (by Avion with a US$25m investment) in an attractive market, and poorly met medical need, we believe the shares are oversold and reiterate our BUY rating and TP of 100p.”
11/2/2021
11:19
sicilian_kan: Even if Lupuzor gets to start a Phase 3 trial, it is now without an SPA. An SPA is FDA confirmation that it is happy with the trial design for approval purposes post trial. "An SPA agreement indicates concurrence by FDA with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, and planned analyses) for a study intended to support a future marketing application". By refusing an SPA on the terms sought by Immupharma, it appears that the FDA is unwilling, at this stage, to endorse Lupuzor's Phase 3 trial design for subsequent approval purposes. So even if Lupuzor gets into Phase 3, shareholders cannot have confidence that a successful Phase 3 will lead to FDA approval. It may do, but equally it may not do. To proceed without an SPA is possible, as is getting approval on a non-SPA endorsed trial, however, to be clear again, the FDA is not endorsing the trial structure for approval purposes. It may do in due course on results, but there is no guarantee of this. . In my view, with Immupharma having asked for an SPA and been turned down, I would be very cautious about investing here. The trading opportunities that arose last time around will just not arise to the same extent. IMM no longer have 100% ownership and if they do get good trial results there is no certainty of outcome. In addition, the results of the previous trial will lurk over investors' heads. I park to one side in this post the PK issues, which are a different matter also needing discussing and which I separate from the above for the purposes of this post.
01/2/2021
21:39
albert arthur: ?Welcome to the Immupharma thread. An SPA application for the lead drug Lupuzor, which hopes to enter its second Phase 3 later this year (2020) is before the FDA with results expected imminently. In addition there is an exciting portfolio.Lupus is a disease where the immune system goes wrong. Your body thinks that it is ill when it is not and the overactive immune system attacks healthy tissue. Many drugs have failed lupus trials because they try to suppress the immune system. The problem with this approach is that if you suppress the immune system too little, then the lupus not go away. If you suppress the immune system too much, you weaken the body to other illnesses.Immupharma's drug Lupuzor is different. It has a novel mechanism of action aimed at modulating the body's immune system (rather than suppressing it) so it does not attack healthy cells, without causing adverse side effects. See the video presentations of Prof Sylvaine Muller at hTTps://player.vimeo.com/video/170358317 and hTTps://vimeo.com/151506805. It also has the potential to halt the progression of the disease in a substantial proportion of patients.The potential clinical market available to Lupuzor is estimated to be in multiple $bns (billions) per year. See the 2019 Annual Report and the below presentation from Immupharma:hTTps://www.immupharma.co.uk/wp-content/uploads/2020/05/ImmuPharma-Annual-Report-31.12.2019-FINAL.pdfhTTps://www.immupharma.co.uk/wp-content/uploads/2020/04/IMM-Corporate-Presentation-website-7-April-2020-FINAL-FINAL.pdfPlease see the information in the scroll box, below the charts, for much more information about Immupharma and Lupuzor.
01/2/2021
18:46
bendaddy: Of course. I realise that. I thought you meant that Immupharma has nothing to do with Covid after Nobbygnome had questioned why their share price is stagnant compared to 'other Covid related biotechs'
24/12/2020
14:53
sharehunter786: ImmuPharma announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals (“Avion”), a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women more) Dermatology and other therapeutic areas. Avion have a strong marketing and commercialisation operation (with over 100 specialist sales reps). Avion has exclusively in-licensed Lupuzor™ for the US market for Lupus (SLE) and other indications and agreed to fund an international Phase III clinical trial for up to US$25m. In addition, Avion will pay up to US$70m in milestones and a royalty stream tiered to 17% has been agreed. We have always believed that ImmuPharma could deliver such a successful deal for the US market. This deal with Avion was aided by the strength of the clinical data (and safety profile) from the Phase III trial announced last year. Our detailed analysis of the respective cohort data, driven by the performance of the peptide in the auto ds-DNA antibody positive patients validated our assumptions of the value of Lupuzor™. We now see Lupuzor™ as having the ability to generate blockbuster sales in the US (£1bn+) alone (previously US and EU combined) – which when coupled with a royalty stream of up to 17% on revenues, could see an annual royalty to ImmuPharma’s bottom line of £170m per year. What is particularly impressive about this deal is not only ImmuPharma’s ability to identify and execute a new licensing partner for Lupuzor™ but also the opportunity available for ImmuPharma to find new distribution and marketing partners outside the US for Lupuzor™, for e.g. in Europe, where a new trial would not even be required given Avion’s funding commitment. This means that there is a distinct possibility that further licensing deals could follow bringing in an attractive additional royalty stream, and additional upfront and milestone payments. Outside of Lupuzor™, we believe that ImmuPharma has the potential to generate news-flow on its other pipeline assets including Nucant and UreKa. Based on the financial assumptions for this deal, and a lower risk profile (reduction in risk premium in our DCF model) we increase our target price (which is 50% discounted) from 176p to 200p / share. BUY.
02/12/2020
07:07
tarny: Immupharma PLC IMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021 02/12/2020 7:00am RNS Non-Regulatory TIDMIMM Immupharma PLC 02 December 2020 ImmuPharma PLC ("ImmuPharma" or the "Company") IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASE(TM) DIGITAL 2021 11-15 January 2021 ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that Dr Tim Franklin, ImmuPharma's Chief Operating Officer, will be presenting at the prestigious Biotech Showcase(TM) Digital 2021. The event will be virtually held between 11 and 15 January 2021. As part of ImmuPharma's participation, an on-demand Company presentation has been provided in advance to the opening of the event. This will allow registered attendees to get access to presentation material prior to the start of the showcase on 11 January 2021. Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
01/12/2020
22:44
albert arthur: This should have images. But sorry it does not, good old ADVFN:IIM FDA background:On September the 7th #IMM dropped a funding RNS for £6.5m at a placing price of 10p. They said this would fund them until 2023:IMM have a drug for Lupus and other autoimmune diseases. On 27 July IMM sent a submission to the FDA for their drug Lupuzor a drug for Lupus. Partnering with Avion Pharmaceuticals.The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025, and is 1.6b today,according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.On the 10th of November the FDA responded agreeing to a type A meeting, note below, IMM have stated the are already producing Lupuzor for Phase 3 Trails: The meeting date is agreed for 4th December 2020.(This Friday).The CEO suggested in a video dated 25th of November under the partnership with Avion Pharmaceuticals the price of the share has now be revalued to a £1 target. See this video 24th November on proactive, 2 mins 38 seconds in:https://www.proactiveinvestors.co.uk/companies/news/934781/immupharmas-partner-avion-set-to-meet-fda-in-december-to-discuss-phase-3-lupus-clinical-trial-934781.htmlFor those who would like to understand a TYPE A meeting, see the below:And also this link:https://www.accessdata.fda.gov/cder/sb-navigate/topic3/topic3/da_01_03_0090.htmThere appears to be only one seller: Lanstead Capital Investors LP. Who bought 20% in April then sold off back to circa 10%. So they may hold the rest.This looks to have serious potential on a cap of just 24m and funding to 2023. FDA type A meeting in the pipeline and drug being made.
15/9/2020
20:09
sicilian_kan: Agreed wigwammer. I'm sure the LTHs here will remember that Immunomedics had epratuzumab, which failed its Phase 3 lupus trial in 2015. The Immunomedics share price tanked, collapsing to $2.05. UCB pulled out of the collaboration. Yesterday, just 5 years later, Immunomedics was bought by Gilead for $88 per share, a 44-bagger! I'm not saying that will happen here. What I am saying is exactly what you have quoted wigwammer, namely that there are two relatively near term opportunities that would dwarf the current market cap if successful and which appear to be completely ignored in the current market cap. And we have the Phase 3 trial that Avion will be running for Immupharma too, in lupus. Trial paid for by Avion with Immupharma retaining all European rights plus getting a royalty of up to 17% on US sales, plus milestones. Plus Immupharma is now fully funded through to the end of 2023, as a result of the recent placing, so no dilution. In short, there are a number of irons in the fire and there should also be (never guaranteed of course) opportunities to top slice like last time and to have a free carry. Below again are the products: BioGlucagon - Existing glucagon products; poor solubility, inconvenient - variable dosing creates risks for patients. BioGlucagon has 100% solubility, can be formulated in pre-filled syringe pens and could be used in insulin pumps. Sales of existing products approx. $500m (p.a.). Bio equivalence study, with potential market launch date in 2022. Partnering opportunities. BioAMP-B - offers a potential improvement on Amphotericin-B (“Amp-B”). Amp-B one of the few effective treatments for serious and life threatening fungal infections such as aspergillosis (lung infection). Leading AMP-B, ‘Ambisome’ causes serious kidney toxicity in c.15% of patients. BioAMP-B’s target profile has superior safety profile to Ambisome. Sales of Ambisome in 2019 were $407m (p.a.). Next steps: Bio equivalence study, with potential market launch date in 2022. See hTTps://www.immupharma.co.uk/wp-content/uploads/2020/04/IMM-Corporate-Presentation-website-7-April-2020-FINAL-FINAL.pdf
Immupharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IMM
Immupharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210411 00:23:01